JP6770524B2 - コクリエート、及び薬理活性物質の組織透過性を高めるためにそれを使用する方法 - Google Patents

コクリエート、及び薬理活性物質の組織透過性を高めるためにそれを使用する方法 Download PDF

Info

Publication number
JP6770524B2
JP6770524B2 JP2017546149A JP2017546149A JP6770524B2 JP 6770524 B2 JP6770524 B2 JP 6770524B2 JP 2017546149 A JP2017546149 A JP 2017546149A JP 2017546149 A JP2017546149 A JP 2017546149A JP 6770524 B2 JP6770524 B2 JP 6770524B2
Authority
JP
Japan
Prior art keywords
create
cocreate
composition according
amphotericin
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017546149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018508523A (ja
JP2018508523A5 (enExample
Inventor
ラファエル ジェイ． マンニーノ
ラファエル ジェイ． マンニーノ
ルーイン ルー
ルーイン ルー
Original Assignee
マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド
マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド, マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド filed Critical マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド
Publication of JP2018508523A publication Critical patent/JP2018508523A/ja
Publication of JP2018508523A5 publication Critical patent/JP2018508523A5/ja
Application granted granted Critical
Publication of JP6770524B2 publication Critical patent/JP6770524B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
JP2017546149A 2015-03-03 2016-03-03 コクリエート、及び薬理活性物質の組織透過性を高めるためにそれを使用する方法 Active JP6770524B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201562127799P 2015-03-03 2015-03-03
US62/127,799 2015-03-03
US201562162425P 2015-05-15 2015-05-15
US62/162,425 2015-05-15
US201562163212P 2015-05-18 2015-05-18
US62/163,212 2015-05-18
US201562239675P 2015-10-09 2015-10-09
US62/239,675 2015-10-09
US201562247641P 2015-10-28 2015-10-28
US62/247,641 2015-10-28
US201562264164P 2015-12-07 2015-12-07
US62/264,164 2015-12-07
PCT/US2016/020722 WO2016141203A1 (en) 2015-03-03 2016-03-03 Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent

Publications (3)

Publication Number Publication Date
JP2018508523A JP2018508523A (ja) 2018-03-29
JP2018508523A5 JP2018508523A5 (enExample) 2019-03-28
JP6770524B2 true JP6770524B2 (ja) 2020-10-14

Family

ID=56848705

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017546149A Active JP6770524B2 (ja) 2015-03-03 2016-03-03 コクリエート、及び薬理活性物質の組織透過性を高めるためにそれを使用する方法

Country Status (8)

Country Link
US (1) US11389407B2 (enExample)
EP (1) EP3265060B1 (enExample)
JP (1) JP6770524B2 (enExample)
KR (1) KR20180004104A (enExample)
CN (1) CN107847443A (enExample)
AU (1) AU2016226151B2 (enExample)
CA (1) CA2978308C (enExample)
WO (1) WO2016141203A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018337955B2 (en) * 2017-09-20 2024-01-18 Atopic Medical, Inc. Compositions and methods for treating and ameliorating respiratory conditions and inflammation of mucosa
CN107621514B (zh) * 2017-11-10 2020-09-29 成都美域高制药有限公司 高效液相色谱法测定磷酸特地唑胺对映异构体含量的方法
KR101989789B1 (ko) * 2017-11-30 2019-06-18 (주) 에이치엔에이파마켐 포스파티딜세린/음이온계면활성제/염화칼슘을 이용한 코킬레이트
WO2019199238A1 (en) * 2018-04-09 2019-10-17 Vet Products Research And Innovation Center Company Limited Inorganic mineral entrapped in nanoparticle production method thereof
JP2022544077A (ja) * 2019-08-13 2022-10-17 マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド クリプトコッカス感染症を治療する方法
WO2024039733A1 (en) 2022-08-16 2024-02-22 Matinas Biopharma Nanotechnologies, Inc. Methods of controlling lipid nanocrystal particle size and lipid nanocrystals produced by such methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871488A (en) 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US5994318A (en) 1993-10-04 1999-11-30 Albany Medical College Cochleate delivery vehicles
US5643574A (en) 1993-10-04 1997-07-01 Albany Medical College Protein- or peptide-cochleate vaccines and methods of immunizing using the same
US6153217A (en) 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
US20030219473A1 (en) * 2002-03-26 2003-11-27 Leila Zarif Cochleates made with purified soy phosphatidylserine
AU2003254598A1 (en) 2002-08-06 2004-02-23 Tuo Jin Cochleates without metal cations as the bridging agents
WO2004064805A1 (en) * 2003-01-15 2004-08-05 Biodelivery Sciences International, Inc. Cochleate preparations of fragile nutrients
US20050013854A1 (en) 2003-04-09 2005-01-20 Mannino Raphael J. Novel encochleation methods, cochleates and methods of use
JP4789208B2 (ja) 2003-04-09 2011-10-12 バイオデリバリー サイエンシーズ インターナショナル インコーポレイティッド タンパク質発現に向けられた渦巻型組成物
WO2005110361A2 (en) * 2004-04-09 2005-11-24 Biodelivery Sciences International, Inc. Nucleotide-cochleate compositions and methods of use
SG190613A1 (en) * 2003-07-16 2013-06-28 Protiva Biotherapeutics Inc Lipid encapsulated interfering rna
JP6347743B2 (ja) * 2011-05-05 2018-06-27 マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド コクリエート組成物およびその製造および使用方法
WO2013085152A1 (en) * 2011-12-07 2013-06-13 Union Korea Pharm Co., Ltd. Combined antibiotics comprising cephalosporins and beta-lactamase inhibitors
MX361155B (es) 2012-07-30 2018-11-28 Matinas Biopharma Nanotechnologies Inc Cocleatos hechos con fosfatidilserina de soja.
CN108136212A (zh) 2015-04-22 2018-06-08 马丁尼斯生物制药纳米技术公司 用于治疗分枝杆菌感染和肺病的组合物和方法
CN107920991A (zh) 2015-06-18 2018-04-17 马丁尼斯生物制药纳米技术公司 治疗炎性疾病或病状的组合物和方法

Also Published As

Publication number Publication date
KR20180004104A (ko) 2018-01-10
EP3265060A4 (en) 2018-08-22
WO2016141203A1 (en) 2016-09-09
CA2978308C (en) 2024-02-13
US20180042849A1 (en) 2018-02-15
EP3265060B1 (en) 2020-10-21
JP2018508523A (ja) 2018-03-29
US11389407B2 (en) 2022-07-19
AU2016226151A1 (en) 2017-09-21
CA2978308A1 (en) 2016-09-09
CN107847443A (zh) 2018-03-27
EP3265060A1 (en) 2018-01-10
AU2016226151B2 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
JP6770524B2 (ja) コクリエート、及び薬理活性物質の組織透過性を高めるためにそれを使用する方法
Molinaro et al. Leukocyte-mimicking nanovesicles for effective doxorubicin delivery to treat breast cancer and melanoma
Jia et al. A novel dexamethasone-loaded liposome alleviates rheumatoid arthritis in rats
TWI732773B (zh) 用於奈米顆粒冷凍乾燥形式的組成物及方法
Zhang et al. Specific surface modification of liposomes for gut targeting of food bioactive agents
US20220054633A1 (en) Nanoparticles, controlled-release dosage forms, and methods for delivering an immunotherapeutic agent
CN117750943B (zh) 靶向动脉粥样硬化脂质体纳米载体递送系统及其制备方法
Gouveia et al. Non-biologic nanodelivery therapies for rheumatoid arthritis
ES2951598T3 (es) Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, preparación y usos de los mismos
CN112535676A (zh) 提高阿霉素肿瘤主动靶向性和肾脏保护的纳米结构脂质制剂及制备方法
JP2021504446A5 (enExample)
JP2023518694A (ja) 感染性疾患又は呼吸器疾患の予防的処置又は曝露後処置に使用するための抗ウイルス剤の組成物
JP2025504405A (ja) 生分解性エステル結合を含むイオン化可能な脂質およびこれを含む脂質ナノ粒子
TW202320803A (zh) 製備脂質體調配物之方法
CN115364218A (zh) 一种特定药脂比的药物组合物在抗肿瘤中的应用
JPWO2005021012A1 (ja) ゲムシタビン封入薬剤担体
US20230129331A1 (en) Liposomal formulations comprising at1 receptor blockers and uses thereof
JP2018517736A (ja) 炎症性疾患又は病態を治療する組成物及び方法
CN111315399A (zh) 用于药物递送的葡萄糖敏感性组合物
KR101002672B1 (ko) 크로몰린 함유 페길화된 리포좀 및 그 제조방법
JP2009292801A (ja) 経口用ナノ脂肪球製剤
CN112870164A (zh) 一种双靶向载药脂质体及其制备方法和应用
Mahmood et al. Engineered Liposomal Nanoparticles and Their Medical Applications
CN114306316B (zh) 一种肿瘤靶向性的复合纳米药物及其制备方法和用途
RU2706356C1 (ru) Способ лечения онкологических заболеваний с помощью инъекций лекарственного препарата

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191126

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200715

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200715

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200728

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200804

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200901

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200925

R150 Certificate of patent or registration of utility model

Ref document number: 6770524

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250